| Hazard Information | Back Directory | [Uses]
SGC-CLK-1 is a potent and selective inhibitor of Cdc2-like kinases CLK1, CLK2, and CLK4. SGC-CLK-1 can inhibit the growth of melanoma and glioblastoma cells[1]. | [Biological Activity]
SGC-CLK-1 is a potent and selective CLK1/2/4 inhibitor (IC50 = 13/4/46 nM by enzyme assay; IC50 = 165/70/100 nM by cell-based NanoBRET assay) with good kinome-wide selectivity (by 403-panel KINOMEscan). SGC-CLK-1 inhibits CLK3 at significantly higher concentrations (IC50 = 363 nM by enzyme assay) and causes only partial STK16 inhibition by cell-based NanoBRET assay. | [References]
[1] Tiek D, et, al. SGC-CLK-1: A chemical probe for the Cdc2-like kinases CLK1, CLK2, and CLK4. Curr Res Chem Biol. 2023:3:100045. DOI:10.1016/j.crchbi.2023.100045 |
|
| Company Name: |
Merck KGaA
|
| Tel: |
21-20338288 |
| Website: |
www.sigmaaldrich.cn |
|